Pharmacological cardioversion for atrial fibrillation/flutter

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

“…The GDG also considered subgroup analyses of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 193 which identified some factors associated with a lower risk of death with rate control. More recent Cochrane reviews 197,198 have reached similar overall conclusions.…”

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

“…The GDG also considered subgroup analyses of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 193 which identified some factors associated with a lower risk of death with rate control. More recent Cochrane reviews 197,198 have reached similar overall conclusions.…”

Pharmacological treatment of persistent atrial fibrillation in the older adult: Evidence-based practice

“…Anticoagulant therapy had often been discontinued for patients who were receiving antiarrthymic agents who maintained sinus rhythm for a minimum of 4 weeks. Cordina and Mead (2006) conclude with a major recommendation to use anticoagulant therapy in all patients with AF, even those who have converted to sinus rhythm. The practice of discontinuing warfarin 4 weeks after converting to sinus rhythm was described as potentially life-threatening as the risk of stroke appears to remain high irrespective of the cardiac rhythm.…”

“…The authors suggested that the trend toward a reduction of thromboembolic stroke in patients in the rate-control group was probably related to the continuation of anticoagulant therapy for a longer period of time than those patients on rhythmcontrol agents. Cordina and Mead (2006) also noted a difference in stroke outcomes when data from the AF-FIRM and PIAF studies were pooled with the RACE and STAF studies. The incidence of stroke in the combined rhythm-control groups was 6.3% compared with a 4.7% incidence in the combined rate-control groups.…”

Systematic Review of Patient Decision Aids for Stroke Prevention Therapy in Atrial Fibrillation Management

“…We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, PUBMED and CINAHL for studies published up to August 2020 that reported on decision aid use within patient populations with nonvalvular AF. Two previously developed Cochrane Review search strategies for decision aids [13] and AF [14] were adapted using the Boolean "and" operator (see Supplementary Material). Additional sources were identified through the review of reference lists of all included articles and consultation with AF and shared decision-making experts.…”

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

“…The GDG also considered subgroup analyses of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 193 which identified some factors associated with a lower risk of death with rate control. More recent Cochrane reviews 197,198 have reached similar overall conclusions.…”

Pharmacological treatment of persistent atrial fibrillation in the older adult: Evidence-based practice

“…Anticoagulant therapy had often been discontinued for patients who were receiving antiarrthymic agents who maintained sinus rhythm for a minimum of 4 weeks. Cordina and Mead (2006) conclude with a major recommendation to use anticoagulant therapy in all patients with AF, even those who have converted to sinus rhythm. The practice of discontinuing warfarin 4 weeks after converting to sinus rhythm was described as potentially life-threatening as the risk of stroke appears to remain high irrespective of the cardiac rhythm.…”

“…The authors suggested that the trend toward a reduction of thromboembolic stroke in patients in the rate-control group was probably related to the continuation of anticoagulant therapy for a longer period of time than those patients on rhythmcontrol agents. Cordina and Mead (2006) also noted a difference in stroke outcomes when data from the AF-FIRM and PIAF studies were pooled with the RACE and STAF studies. The incidence of stroke in the combined rhythm-control groups was 6.3% compared with a 4.7% incidence in the combined rate-control groups.…”

Systematic Review of Patient Decision Aids for Stroke Prevention Therapy in Atrial Fibrillation Management

“…We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, PUBMED and CINAHL for studies published up to August 2020 that reported on decision aid use within patient populations with nonvalvular AF. Two previously developed Cochrane Review search strategies for decision aids [13] and AF [14] were adapted using the Boolean "and" operator (see Supplementary Material). Additional sources were identified through the review of reference lists of all included articles and consultation with AF and shared decision-making experts.…”

Economic modelling of diagnostic and treatment pathways in National Institute for Health and Care Excellence clinical guidelines: the Modelling Algorithm Pathways in Guidelines (MAPGuide) project

“…The GDG also considered subgroup analyses of the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) trial, 193 which identified some factors associated with a lower risk of death with rate control. More recent Cochrane reviews 197,198 have reached similar overall conclusions.…”

Pharmacological treatment of persistent atrial fibrillation in the older adult: Evidence-based practice

“…Anticoagulant therapy had often been discontinued for patients who were receiving antiarrthymic agents who maintained sinus rhythm for a minimum of 4 weeks. Cordina and Mead (2006) conclude with a major recommendation to use anticoagulant therapy in all patients with AF, even those who have converted to sinus rhythm. The practice of discontinuing warfarin 4 weeks after converting to sinus rhythm was described as potentially life-threatening as the risk of stroke appears to remain high irrespective of the cardiac rhythm.…”

“…The authors suggested that the trend toward a reduction of thromboembolic stroke in patients in the rate-control group was probably related to the continuation of anticoagulant therapy for a longer period of time than those patients on rhythmcontrol agents. Cordina and Mead (2006) also noted a difference in stroke outcomes when data from the AF-FIRM and PIAF studies were pooled with the RACE and STAF studies. The incidence of stroke in the combined rhythm-control groups was 6.3% compared with a 4.7% incidence in the combined rate-control groups.…”

Systematic Review of Patient Decision Aids for Stroke Prevention Therapy in Atrial Fibrillation Management

“…We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, PUBMED and CINAHL for studies published up to August 2020 that reported on decision aid use within patient populations with nonvalvular AF. Two previously developed Cochrane Review search strategies for decision aids [13] and AF [14] were adapted using the Boolean "and" operator (see Supplementary Material). Additional sources were identified through the review of reference lists of all included articles and consultation with AF and shared decision-making experts.…”